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Editors’ NotesAn Intervention on Therapy
Much discussed of late has been the concept of ‘‘stem cell tourism,’’ or the growing trend of patients leaving their home
environment to seek stem cell treatments in other locales, which are often provided at great expense and are suspected
by many to be lacking in scientific support for both safety and efficacy. In an attempt to curtail misrepresentation of putative
stem cell therapies to potential clients, an international ISSCR task force has developed Clinical Guidelines for stem-cell-
based treatments. These guidelines are summarized in an accompanying Commentary article in the ISSCR section of this
issue. The proposed standards may not be binding, but the task force’s efforts offer an invaluable resource to institutions
working to develop clinical applications of stem cells, as well as to patients who seek to evaluate potential intervention options
available to them. In addition, a Correspondence article from Caulfield and colleagues assesses the portrayal of stem cell
applications offered by a host of commercial operations, as described on their company websites. The content analysis of
these sites, as compared to available peer-reviewed published scientific literature, reveals that by and large the websites offer
an overly optimistic view of the efficacy of their wares.
Dishing Disease Models
Determining the origin and pathogenesis of complex human ailments is exceedingly challenging, and deconstructed disease
models can offer insight by taking a reductionist approach. In this issue, two independent studies from the Gage and Eggan
laboratories reveal that hESC-derived motor neurons are highly and specifically susceptible to killing by
neighboring astrocytes that harbor an ALS-causing mutation of the SOD1 gene. Both groups use their
respective in vitro systems to identify soluble mediators of the astrocyte-dealt death, including super-
oxide and prostaglandin. In another research article, Ratner and colleagues reveal that EGF receptor
expression marks a population of human and mouse neurofibromal cells that exhibit tumorigenic potential.
These Schwann cell tumors are typical of patients with neurofibromatosis type 1, and thus the model
system may help identify and test signaling pathways that can be targeted to develop potential disease
treatments.
Blood Crossing Boundaries
Two articles in this issue reveal interesting aspects of HSCs that connect them to nonhematopoietic systems. Trumpp and
colleagues generated HSCs that do not express either N-myc or c-myc. Proliferation and self-renewal of the mutant HSCs
are altered during steady-state conditions, and this population also exhibits a specific reduction in survival.
The cells accumulate cytoplasmic Granzyme B, previously only observed in cytotoxic, differentiated
immune lineages. The embryonic origin of primitive blood precursors has been open to some question
and debate within the hematopoietic field. Recent technical advances that have helped to clarify this issue
are discussed in the Minireview from Yoder and colleagues, including a research article in this issue from
the Iruela-Arispe laboratory. In their study, the authors use lineage tracing to reveal that specific regions
of the embryonic endothelium not only support hematopoietic progeny, but also give rise to early
HSCs. This direct connection of hematopoietic and endothelial lineages in vivo offers a striking advance
in the understanding of blood cell development.
Pluripotency for Everyone
The attraction of using direct reprogramming methods to generate pluripotent cells from somatic tissues is largely attributed
to the potential of iPSCs in both clinical and basic research applications, as well as to the fact that direct reprogramming over-
comes many practical and ethical limitations of other pluripotent techniques. However, the procedures required to induce
pluripotency using defined factors require a specific skill set and a certain degree of expertise. In their Protocol Review,
Maherali and Hochedlinger not only offer readers a summary of the current requirements for inducing pluripotency in somatic
cells, but also outline and compare the various approaches used by different laboratories across the world. The authors also
comment on the range of assays used to assess the pluripotency of resulting cell lines and offer some suggestions as to the
minimal criteria that can be used to verify successful reprogramming. Also in this issue, Deng and colleagues describe the
isolation of iPSCs from monkey cells, demonstrating that the same reprogramming factors that work for mouse and human
cells are also sufficient to induce pluripotency in another species.Cell Stem Cell 3, December 4, 2008 ª2008 Elsevier Inc. xv
